Age-Related Macular Degeneration and Chakshuya Herbs: A 2026 Review

Dr. Meera Iyer — Mon, 06 Jul 2026 12:00:00 +0000

Age-related macular degeneration (AMD) remains one of the most important causes of irreversible vision loss in later life. Global estimates project that AMD will affect about 288 million people by 2040, and it is a major cause of blindness in higher-income countries. Modern care has improved substantially: anti-VEGF injections are central for neovascular or “wet” AMD, AREDS2 nutritional support is used for suitable intermediate AMD patients, and intravitreal complement inhibitors are now available for geographic atrophy in selected cases. Even with these advances, AMD still requires long-term monitoring, and many patients look for safe adjunctive measures that support retinal resilience without delaying ophthalmic treatment.

Within this background, Ayurvedic Chakshushya and Rasayana dravyas deserve careful, proportionate attention. The strongest human AMD data among botanicals discussed here belong to saffron, while Triphala, Yashtimadhu, and Netra Tarpana are better understood as classical and mechanistic adjuncts that may support ocular tissues, inflammation balance, and long-term eye nourishment under professional care.

Ayurvedic Theory of Eye Disease: Drishti and Alochaka Pitta

Classical Ayurveda does not name age-related macular degeneration as a modern retinal diagnosis, but disorders of vision are discussed under Drishtigata Rogas, including Timira and related states of progressive visual dimness. Alochaka Pitta is described as the Pitta subtype associated with the eyes and visual perception, while the Drishti is the visual apparatus through which sight is apprehended. In Ayurvedic interpretation, chronic retinal degeneration is approached through disturbance of Alochaka Pitta, age-related Vata aggravation, depletion of ocular nourishment, and gradual impairment of the channels and tissues supporting vision.

The classical aim is not to replace retinal examination or modern AMD treatment, but to preserve visual function through Vata-Pitta pacification, Chakshushya dravyas, Rasayana support, suitable ghrita-based therapies, and disciplined eye care. Timira descriptions in the classical ophthalmic sections emphasise progressive blurring, dimness, and altered perception; these are best used as Ayurvedic clinical frameworks rather than one-to-one disease labels for AMD.

Herb 1: Saffron (Crocus sativus) — The Retinal Function Support Herb

Kumkuma or saffron is listed in the Ayurvedic Pharmacopoeia of India as the dried stigma and style of Crocus sativus. Its recorded Ayurvedic profile includes Katu and Tikta rasa, Snigdha guna, Ushna virya, Katu vipaka, and actions that include Vatahara, Varnya, Vishaghna, Shleshmahara, Rasayana, and use in Drishti Roga. Its important constituents include crocin, picrocrocin, and volatile aromatic compounds, which also make saffron one of the more biologically plausible ocular botanicals for retinal support.

Saffron has the clearest human AMD signal in this group. A randomized crossover clinical trial in early AMD used 20 mg daily saffron for three months and reported improved focal electroretinogram flicker sensitivity, suggesting measurable macular function change. Follow-up work continued this 20 mg daily model, and other AMD trials have used 20–30 mg daily saffron supplementation with visual function outcomes such as mfERG, BCVA, and contrast-related measures. The practical clinical message is conservative: saffron is not an AMD cure, but it is the most substantiated botanical adjunct discussed here.

Practical range: clinical AMD trials commonly used 20 mg daily saffron, with some work using 30 mg daily. The Ayurvedic Pharmacopoeia lists 25–50 mg as the dose for Kumkuma. This should not be converted into gram-level daily saffron dosing. Use only good-quality saffron or a properly standardised product, and avoid high-dose saffron, especially in pregnancy or when medically vulnerable.

Herb 2: Triphala — Classical Chakshushya and Rasayana Support

Triphala combines Haritaki, Bibhitaki, and Amalaki, and is widely used in Ayurveda as a Rasayana and supportive formulation for digestion, elimination, and tissue balance. In eye care, Triphala is traditionally used internally and in ghrita-based preparations, including Triphala Ghrita, because the formulation is considered supportive for Netra Rogas when selected appropriately by a practitioner.

The retinal relevance of Triphala is best framed through its phytochemical and pre-clinical profile rather than as a proven stand-alone AMD treatment. Gallic acid, chebulagic acid, chebulinic acid, tannins, and related polyphenols are important Triphala-associated compounds. Experimental retinal endothelial work with Triphala-derived compounds has described modulation of inflammatory and pro-angiogenic pathways, and broader angiogenesis work has connected Triphala and chebulinic acid with VEGF-related signalling. This makes Triphala a reasonable Chakshushya-Rasayana adjunct in an Ayurvedic plan focused on long-term retinal nourishment, bowel regularity, and inflammation balance, but not a substitute for AREDS2 guidance, anti-VEGF treatment, or geographic atrophy care when indicated.

Practical use: Triphala dosing and form should be individualised. Churna, tablets, decoction-style preparations, and ghrita-based approaches are not interchangeable. In older AMD patients, strong laxative use can be inappropriate; the goal is gentle support, not aggressive purgation. Patients with frailty, dehydration risk, bowel disease, or multiple medications should use Triphala only under qualified guidance.

Herb 3: Yashtimadhu (Glycyrrhiza glabra) — Chakshushya Support with Safety Boundaries

Yashtimadhu, also known as licorice root, is listed in the Ayurvedic Pharmacopoeia of India as the dried root and stolon of Glycyrrhiza glabra. Its classical profile is Madhura rasa, Guru and Snigdha guna, Shita virya, Madhura vipaka, and actions including Chakshushya, Vata-Pitta-jit, Raktaprasadana, Shothahara, and Rasayana. This supports its inclusion in classical eye-health discussions, particularly where Pitta irritation, dryness, and tissue depletion are part of the Ayurvedic assessment.

The modern ocular interest in licorice is mainly pre-clinical. Isoliquiritigenin, a licorice-derived compound, has been evaluated in experimental ocular angiogenesis models, including choroidal and retinal neovascularisation models. This gives Yashtimadhu a plausible place as a supportive Chakshushya dravya, especially in a Vata-Pitta framework, but oral Yashtimadhu should not be presented as an anti-VEGF replacement or as a proven AMD therapy.

Safety boundary: non-deglycyrrhizinated licorice can raise blood pressure, lower potassium, promote fluid retention, and interact with medicines such as diuretics, antihypertensives, corticosteroids, and digoxin. Long-term Yashtimadhu use is inappropriate without medical supervision in patients with hypertension, kidney disease, heart disease, arrhythmia risk, pregnancy, or complex medication schedules.

Netra Tarpana for AMD Support

Netra Tarpana is a classical Netra Kriyakalpa in which warm ghrita or medicated ghrita is retained over the closed or blinking eyes within a dough boundary for a prescribed duration. In practice, preparations such as plain cow ghee, Triphala Ghrita, or other physician-selected ghritas may be used depending on the condition, season, strength of the patient, and ocular findings.

For AMD, Netra Tarpana should be understood as a supervised supportive therapy rather than a retinal drug delivery substitute. Its classical rationale is Snehana, Brimhana, Chakshushya action, and relief of ocular dryness or strain. Institutional Ayurvedic clinical-research listings include Triphala Ghrita and Anu Taila protocols for dry AMD or Jarajanya Drishtigata Roga, and separate clinical literature has evaluated Tarpana-like ghrita therapies in dry eye. In an AMD patient, Tarpana belongs only within coordinated care that includes regular ophthalmology review, OCT or fundus monitoring where advised, and prompt treatment of wet AMD symptoms.

Evidence Summary Table

The following table separates human AMD evidence from classical use and pre-clinical rationale so that each intervention is placed in its proper clinical context.

Herb / Intervention	Evidence Type	Typical Use Range	Most Appropriate AMD Role
Saffron (Kumkuma, Crocus sativus)	Human AMD trials plus Ayurvedic Pharmacopoeia support for Drishti Roga	20 mg daily in several AMD trials; API dose 25–50 mg	Adjunctive retinal function support in early or mild-to-moderate AMD under ophthalmic monitoring
Triphala	Classical Chakshushya-Rasayana use and retinal/angiogenesis pre-clinical rationale	Individualised churna, tablet, decoction, or ghrita form	Supportive Rasayana for inflammation balance, digestion, elimination, and long-term ocular nourishment
Yashtimadhu (Glycyrrhiza glabra)	API-listed Chakshushya dravya with experimental ocular angiogenesis data	API powder dose 2–4 g, but long-term use requires caution	Selected Vata-Pitta and tissue-support cases; avoid unsupervised use in blood pressure or potassium-risk patients
Netra Tarpana	Classical Netra Kriyakalpa and clinical use in ocular surface disorders; AMD protocols listed in Ayurvedic clinical-research settings	Clinician-administered sessions using suitable ghrita	Supportive ocular nourishment and dryness/strain care, not replacement for retinal AMD treatment
Conventional AMD care	Ophthalmology standard of care	AREDS2 when appropriate; anti-VEGF for wet AMD; complement inhibitors for selected geographic atrophy	Primary disease monitoring and sight-preserving treatment pathway

For related eye health content, our guide to Ayurvedic under-eye care and Netra vitality covers complementary eye support. The antioxidant and rejuvenation principles relevant to long-term ocular tissue care are also discussed in our Rasayana therapy and longevity research review.

References and Further Reading

The references below support the conventional AMD background, the classical Ayurvedic framing, and the botanical or procedural claims retained in this article.

Wong WL et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040.
International Agency for the Prevention of Blindness: AMD overview and global blindness context.
National Eye Institute: AREDS/AREDS2 and wet AMD treatment guidance.
American Academy of Ophthalmology: geographic atrophy treatment overview.
Ayurvedic Pharmacopoeia of India: Kumkuma and Yashti monographs.
Sushruta Samhita and Ashtanga Hridaya ophthalmology sections on Drishti and Timira.
Falsini et al., Piccardi et al., Lashay et al., and Broadhead et al. on saffron supplementation in AMD.
Retinal endothelial and ocular angiogenesis literature on Triphala-derived compounds and isoliquiritigenin.
Clinical and classical literature on Netra Tarpana and Triphala Ghrita in eye care.

Safety and Clinical Use

Age-related macular degeneration is a serious ophthalmic condition requiring regular monitoring by an ophthalmologist, including retinal examination and OCT imaging when advised. The herbs and therapies described here are adjunctive supports, not replacements for AREDS2 guidance, anti-VEGF injections for wet AMD, complement-inhibitor therapy for geographic atrophy, or any other treatment recommended by an eye specialist. Sudden distortion, central dark spots, new blurring, flashes, floaters, or rapid vision change require urgent eye evaluation. Consult a qualified Ayurvedic practitioner, ophthalmologist, and healthcare provider before starting saffron, Triphala, Yashtimadhu, Netra Tarpana, supplements, or therapeutic protocols, especially if pregnant, elderly, hypertensive, diabetic, medically fragile, or taking prescription medication.

Macular Degeneration – Ayurved Healing